Search

Important Information for the Hemophilia Community Regarding Triad Group’s Alcohol Prep Products and Bayer’s BayCuff™ and First Aid Kit… learn more »

Important Safety Information
Prescribing Information »

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. Continue Reading Below »

Resources for Your Patients

Insurance Programs: The Bayer HealthCare Factor Solutions program can provide your patients with convenient insurance support to ensure they receive their Kogenate^® FS, Antihemophilic Factor (Recombinant) with BIO-SET^®.

Free Product Trial Program: Bayer HealthCare provides patients with hemophilia A the opportunity to experience the benefits of factor VIII therapy with Kogenate FS with BIO-SET treatment — for free.*

EZ-Log: Flexible electronic patient diary to help patients, caregivers, and healthcare professionals track and report treatment with accuracy, convenience, and security.

BayCuff^™: The BayCuff^™ self-infusion training program may help you learn how to self-infuse with Factor VIII (FVIII).

Healthy Decisions, Healthy Joints: This learning tool may teach people with hemophilia A how to optimize joint health

*Up to 6 free doses to a maximum of 5,000 IU for new patients and 20,000 IU for previously treated patients.

INDICATIONS & USAGE

Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

IMPORTANT SAFETY INFORMATION

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information, please see the full prescribing information.

Prescribing Information | Privacy Policy | Terms of Use | Sitemap

© 2010 Bayer HealthCare Pharmaceuticals Inc. All rights reserved.
BAYER, the Bayer Cross, and KOGENATE are registered trademarks of Bayer.
BIO-SET is a trademark of Biodome SAS.

Kogenate FS Antihemophilic Factor (Recombinant) with BIO-SET Needleless Reconstitution System